Dette kan resultere i en stigning i PDE5- hæmmer associerede bivirkninger, herunder hypotension, visuelle ændringer og priapismus.
Based on data for ritonavir and other protease inhibitors, plasma concentrations of PDE5 inhibitors (e. g. sildenafil and vardenafil) are expected to substantially increase when co-administered with Telzir with ritonavir and may result in an increase in PDE5 inhibitor associated adverse reactions, including hypotension, visual changes and priapism.